What is the current share price of Waypoint REIT Limited (WPR)? Waypoint REIT Limited's (WPR) current share price is $2.44. This constitutes a price movement of 2.09% when compared to the share price ...

GSK plc announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted indications are for ...

Thymic stromal lymphopoietin (TSLP) and interleukin (IL)-4 levels are elevated in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and correlated with increased preoperative fractional ...

If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing interval for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal ...

LONDON - GSK plc (LSE/NYSE: GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...

Kaivan Khavandi, SVP at GSK, stated, "Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma and CRSwNP for ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing Submissions based on data from positive SWIFT and ANCHOR trials SWIFT-1 and -2 showed depemokimab reduced ...

Abstract: Chronic rhinosinusitis with nasal polyps (CRSwNP), as one of the most common chronic nasal inflammations, has been a major research focus in the field of rhinology due to its complex and ...